Siglec-7 Antibody (A-7): sc-398919

Siglec-7 Antibody (A-7) is a mouse monoclonal IgG1 kappa light chain antibody that detects the Siglec-7 protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Siglec-7 (A-7) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates, providing versatility for different experimental needs. Siglec-7 plays a crucial role in the immune system, particularly in the regulation of natural killer (NK) cell activity; Siglec-7 is primarily expressed on monocytes and resident blood cells, where Siglec-7 inhibits NK cell cytotoxicity, thereby modulating immune responses. This inhibition is vital for maintaining immune homeostasis and preventing excessive tissue damage during immune reactions. Additionally, Siglec-7 is part of a larger family of sialic acid-binding immunoglobulin-like lectins (siglecs), which are known to interact with sialylated ligands, influencing cell-cell communication and immune signaling. Understanding Siglec-7 function and interactions is essential for developing therapeutic strategies targeting immune modulation in various diseases, including cancer and autoimmune disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Siglec-7 Antibody (A-7) References:

1. New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins.  |  Brinkman-Van der Linden, EC. and Varki, A. 2000. J Biol Chem. 275: 8625-32. PMID: 10722702
2. Loss of N-glycolylneuraminic acid in human evolution. Implications for sialic acid recognition by siglecs.  |  Brinkman-Van der Linden, EC., et al. 2000. J Biol Chem. 275: 8633-40. PMID: 10722703
3. Ultrastructural localisation of sialoadhesin (siglec-1) on macrophages in rodent lymphoid tissues.  |  Schadee-Eestermans, IL., et al. 2000. Immunobiology. 202: 309-25. PMID: 11131149
4. Loss of disialyl Lewis(a), the ligand for lymphocyte inhibitory receptor sialic acid-binding immunoglobulin-like lectin-7 (Siglec-7) associated with increased sialyl Lewis(a) expression on human colon cancers.  |  Miyazaki, K., et al. 2004. Cancer Res. 64: 4498-505. PMID: 15231659
5. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9.  |  Ikehara, Y., et al. 2004. J Biol Chem. 279: 43117-25. PMID: 15292262
6. Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cells.  |  Lock, K., et al. 2004. Immunobiology. 209: 199-207. PMID: 15481154
7. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells.  |  Avril, T., et al. 2004. J Immunol. 173: 6841-9. PMID: 15557178
8. Glycan array screening reveals a candidate ligand for Siglec-8.  |  Bochner, BS., et al. 2005. J Biol Chem. 280: 4307-12. PMID: 15563466
9. Role of Siglec-7 in apoptosis in human platelets.  |  Nguyen, KA., et al. 2014. PLoS One. 9: e106239. PMID: 25230315
10. Activation of Siglec-7 results in inhibition of in vitro and in vivo growth of human mast cell leukemia cells.  |  Landolina, N., et al. 2020. Pharmacol Res. 158: 104682. PMID: 32035162
11. Fusobacterium nucleatum subsp. nucleatum RadD binds Siglec-7 and inhibits NK cell-mediated cancer cell killing.  |  Galaski, J., et al. 2024. iScience. 27: 110157. PMID: 38952680
12. Effect of Hypoxia on Siglec-7 and Siglec-9 Receptors and Sialoglycan Ligands and Impact of Their Targeting on NK Cell Cytotoxicity.  |  Nawafleh, H., et al. 2024. Pharmaceuticals (Basel). 17: PMID: 39598355

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Siglec-7 Antibody (A-7) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-Siglec-7 Antibody (A-7) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Siglec-7 Antibody (A-7) Specifications

Alternate Product Name: Siglec-7

Product Clone Name: A-7

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 387-409

Epitope Target: Siglec-7

Epitope Species: human

Product Reactivity/Detection: Siglec-7

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for Siglec-7 Antibody (A-7): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin